Medications for Hidradenitis Suppurativa
These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in Hidradenitis Suppurativa.
Found 7 Approved Drugs for Hidradenitis Suppurativa
Adalimumab
Brand Names
Adalimumab-aacf, Humira
Adalimumab
Brand Names
Adalimumab-aacf, Humira
Form: Kit
Method of administration: Subcutaneous
FDA approval date: December 31, 2002
HUMIRA is a tumor necrosis factor (TNF) blocker indicated for: Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis.
Adalimumab-ADAZ
Brand Names
Amjevita, Adalimumab-bwwd, Adalimumab, Yusimry, Hyrimoz, Hadlima
Adalimumab-ADAZ
Brand Names
Amjevita, Adalimumab-bwwd, Adalimumab, Yusimry, Hyrimoz, Hadlima
Form: Injection, Kit, Solution
Method of administration: Subcutaneous
FDA approval date: January 31, 2023
Classification: Tumor Necrosis Factor Blocker
Plaque Psoriasis HYRIMOZ is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. HYRIMOZ should only be administered to patients who will be closely monitored and have regular follow-up visits with a physician. Ulcerative Colitis HYRIMOZ is indicated for the treatment of moderately to severely active ulcerative colitis in adult patients. Limitations of Use: The effectiveness of adalimumab products has not been established in patients who have lost response to or were intolerant to TNF-blockers [see Clinical Studies (1. HYRIMOZ is a tumor necrosis factor (TNF)-blocker indicated for: Rheumatoid Arthritis (RA).
Adalimumab-FKJP
Brand Names
HULIO, Adalimumab
Adalimumab-FKJP
Brand Names
HULIO, Adalimumab
Form: Kit
FDA approval date: July 02, 2023
Adalimumab-fkjp is a tumor necrosis factor (TNF) blocker indicated for: Rheumatoid Arthritis (RA).
Adalimumab-AATY
Brand Names
Yuflyma, Adalimumab
Adalimumab-AATY
Brand Names
Yuflyma, Adalimumab
Form: Kit
FDA approval date: May 23, 2023
Adalimumab-aaty is a tumor necrosis factor (TNF) blocker indicated for: Rheumatoid Arthritis (RA).
Showing 1-5 of 7
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances